To include your compound in the COVID-19 Resource Center, submit it here.

Amgen, Simcere partner for biosimilars in China

Amgen Inc. (NASDAQ:AMGN) and Simcere Pharmaceutical Group (Nanjing, China) partnered to exclusively co-develop and commercialize biosimilars in China. The agreement includes four biosimilars from Amgen in inflammation and oncology, including ABP 501 and Mvasi bevacizumab-awwb

Read the full 357 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE